Eli Lilly hits record high after earnings, Mounjaro hype. Here's what the pros are saying
Market Movers rounded up the best reactions from investors and analysts on Eli Lilly . The experts, including Jim Cramer , discussed the drugmaker after it reported second-quarter revenue and earnings Tuesday that beat Wall Street estimates. The company also raised its full-year guidance as quarterly profit soared 85% from the same period last year.
Shares of Eli Lilly hit an all-time high during intraday trading, perhaps also getting a boost from a Novo Nordisk trial. The study found Novo Nordisk's obesity drug Wegovy, which shares some similarities with Lilly's Mounjaro, cut the risk of heart disease in participants by 20%. Eli Lilly's stock finished the day about 14.9% higher. LLY is currently held in Cramer's Charitable Trust portfolio.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Eli Lilly Raises Forecasts with Diabetes Drug Mounjaro's Strong PerformancePharmaceutical company Eli Lilly has increased its forecasts after its diabetes drug Mounjaro delivers positive results, boosting the company's outlook.
Weiterlesen »
Soaring Sales of Diabetes Drug Mounjaro Propel Eli Lilly to New HeightsEli Lilly's diabetes treatment Mounjaro, known for its off-label use as a weight-loss drug, exceeded Wall Street's expectations by generating nearly $1 billion in sales during the second quarter. The drug's success reflects the growing demand for weight-loss treatments, prompting regulators to consider approving it for this purpose as well.
Weiterlesen »
Morgan Stanley predicts Eli Lilly shares to rally on Novo's obesity drug dataMorgan Stanley believes that the positive data on Novo Nordisk's obesity drug Wegovy will also benefit Eli Lilly, leading to a potential increase in its stock value. Novo Nordisk's shares surged by 15% following the release of late-stage trial data, which demonstrated that Wegovy reduced the risk of major cardiovascular events by 20% compared to a placebo.
Weiterlesen »
Ozempic and Mounjaro makers sued by patient alleging ‘severe gastrointestinal issues'The medications are used to treat Type 2 diabetes and have become popular weight-loss drugs.
Weiterlesen »
Patient Sues Ozempic and Mounjaro Makers Over Severe Gastrointestinal IssuesA patient from Louisiana has filed a lawsuit against Novo Nordisk, the maker of Ozempic, and Eli Lilly, the maker of Mounjaro, alleging that they failed to adequately warn about the potential adverse side effects of the medications, including the risk of gastroparesis.
Weiterlesen »
Nektar Therapeutics’ stock jumps premarket after it says data presented by Eli Lilly for a skin treatment was incorrectly calculatedNektar Therapeutics’ stock jumped 12.7% in premarket trade Monday, after the company said that efficacy data previously generated by its former partner Eli...
Weiterlesen »